Dapagliflozin-d5 – 500 µg

Brand:
Cayman
CAS:
1204219-80-6
Storage:
4
UN-No:
Non-Hazardous - /

Dapagliflozin-d5 is intended for use as an internal standard for the quantification of dapagliflozin (Item No. 11574) by GC- or LC-MS. Dapagliflozin is a first generation, selective sodium-glucose linked transporter (SGLT) inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM; EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM).{20896} After single oral doses ranging from 0.1 to 1.0 mg/kg, dapagliflozin increases urinary glucose excretion in both normal and diabetic rats, improves glucose tolerance in normal rats, and reduces hyperglycemia in Zucker diabetic fatty rats.{22762} Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg dapagliflozin, fasting and fed glucose levels have been shown to be significantly lowered as a result of increased glucose utilization accompanied by reduced glucose production.  

 

Out of stock

SKU: 22611 - Category:

Description

An internal standard for the quantification of dapagliflozin by GC- or LC-MS,


Formal name: (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-(ethoxy-1,1,2,2,2-d5)phenyl]methyl]phenyl]-D-glucitol

Synonyms: 

Molecular weight: 413.9

CAS: 1204219-80-6

Purity: ≥99% deuterated forms (d1-d5)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes